Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients

AIDS

Volumn 15, Issue 17, 2001, Pages 2334-2335

  Fätkenheuer, Gerd ^a   Römer, Katja ^a   Kamps, Robert ^a   Salzberger, Bernd ^a   Burger, David ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; LOPINAVIR; NEVIRAPINE; RITONAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MIXTURE; DRUG MONITORING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NEVIRAPINE; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; SULFONAMIDES; VIRAL LOAD;

EID: 0035941398     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111230-00021     Document Type: Article

References (6)

1. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers
2. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography
3. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
4. Kaletra
5. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24 week safety/efficacy evaluation in multiple PI-experienced patients
6. Amprenavir plasma concentrations are dramatically decreased by the association with ABT378/r in HIV infected patients